BR9702238A - Use of a compound compound for use in the treatment or prevention of a disease or condition involving cytokine production or calling for use in the identification process - Google Patents

Use of a compound compound for use in the treatment or prevention of a disease or condition involving cytokine production or calling for use in the identification process

Info

Publication number
BR9702238A
BR9702238A BR9702238A BR9702238A BR9702238A BR 9702238 A BR9702238 A BR 9702238A BR 9702238 A BR9702238 A BR 9702238A BR 9702238 A BR9702238 A BR 9702238A BR 9702238 A BR9702238 A BR 9702238A
Authority
BR
Brazil
Prior art keywords
compound
calling
disease
prevention
treatment
Prior art date
Application number
BR9702238A
Other languages
Portuguese (pt)
Inventor
Paul Thornalley
Original Assignee
Wivenhoe Techn Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wivenhoe Techn Ltd filed Critical Wivenhoe Techn Ltd
Publication of BR9702238A publication Critical patent/BR9702238A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9702238A 1996-05-25 1997-05-23 Use of a compound compound for use in the treatment or prevention of a disease or condition involving cytokine production or calling for use in the identification process BR9702238A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611046.5A GB9611046D0 (en) 1996-05-25 1996-05-25 Pharmacological compounds
PCT/GB1997/001415 WO1997045417A1 (en) 1996-05-25 1997-05-23 Cytokine production inhibitors, formulations thereof and their use in medicine, and methods for their identification

Publications (1)

Publication Number Publication Date
BR9702238A true BR9702238A (en) 1999-07-27

Family

ID=10794362

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9702238A BR9702238A (en) 1996-05-25 1997-05-23 Use of a compound compound for use in the treatment or prevention of a disease or condition involving cytokine production or calling for use in the identification process

Country Status (10)

Country Link
EP (1) EP0859762A1 (en)
JP (1) JPH11510521A (en)
AU (1) AU2910397A (en)
BR (1) BR9702238A (en)
CA (1) CA2227811A1 (en)
GB (1) GB9611046D0 (en)
HU (1) HUP9902796A3 (en)
IL (1) IL123033A0 (en)
NO (1) NO980299L (en)
WO (1) WO1997045417A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2005264917A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
CN1968945A (en) 2004-06-16 2007-05-23 惠氏公司 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
BRPI0606690A2 (en) 2005-01-14 2009-07-14 Wyeth Corp compound; use of the compound to treat a disease or disorder associated with excessive bace activity; and pharmaceutical composition
BRPI0607094A2 (en) 2005-02-01 2009-08-04 Wyeth Corp compound of the formula i; use of the compound for the treatment of a disease or disorder associated with excessive baby activity in a patient who needs it; use of the compound to modulate the bace activity; and pharmaceutical composition
KR20070102751A (en) 2005-02-14 2007-10-19 와이어쓰 AZOLYLACYLGUANIDINES AS beta;-SECRETASE INHIBITORS
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
CA2623245A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
AR065814A1 (en) 2007-03-23 2009-07-01 Wyeth Corp DERIVATIVES OF 5-PHENYLIMIDAZOLONE, INHIBITORS OF BETA-SECRETASA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES TO PREVENT AND / OR TREAT ASSOCIATED DISORDERS AT LEVELS BETA-AMYLOOES ELEVATED.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005205A (en) * 1974-04-24 1977-01-25 Smith Kline & French Laboratories Limited Compositions and methods for inhibiting H2 histamine receptors
GR79384B (en) * 1982-08-20 1984-10-22 Hoechst Uk Ltd
PT77842B (en) * 1982-12-21 1986-05-05 Pfizer Process for preparing dihydropyridines
GB8311443D0 (en) * 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
AU5428686A (en) * 1985-03-12 1986-09-18 Smith Kline & French Laboratories Limited Imidazolinone and thiazolinone derivatives
FI902321A0 (en) * 1989-05-19 1990-05-09 Eisai Co Ltd BUTENSYRADERIVAT.
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives

Also Published As

Publication number Publication date
IL123033A0 (en) 1998-09-24
HUP9902796A3 (en) 2000-07-28
MX9800670A (en) 1998-09-30
NO980299D0 (en) 1998-01-23
CA2227811A1 (en) 1997-12-04
HUP9902796A2 (en) 2000-04-28
GB9611046D0 (en) 1996-07-31
EP0859762A1 (en) 1998-08-26
AU2910397A (en) 1998-01-05
NO980299L (en) 1998-03-24
JPH11510521A (en) 1999-09-14
WO1997045417A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
BR9609780A (en) Compound use of a compound process for the treatment of pharmaceutical composition conditions processes for preparing a pharmaceutical composition and for preparing a compound
BR9406128A (en) Use of a process compound for the treatment and / or prevention of psychotic disorders compound pharmaceutical composition processes for the preparation of a compound and a pharmaceutical composition
BR9600148A (en) 2,8-disubstituted quinazolinones process for their preparation and medication use
BR9407869A (en) Combination of pharmaceutical composition and process for the treatment of osteoporosis
BR9404203A (en) Compounds, process for their preparation, medication, use of said compounds and process for the treatment or prevention of central nervous disorders
BR9408148A (en) Process for the treatment of compound arrhythmia and pharmaceutical formulation
BR9503812A (en) Compound pharmaceutical composition use method of treatment of a human process for the preparation of a compound
BR1100850A (en) Compound, process for the preparation of a compound, and pharmaceutical composition
BR9612204A (en) Compound use of the compound Pharmaceutical composition and process for preparing the compound and for treating pain
BR9702238A (en) Use of a compound compound for use in the treatment or prevention of a disease or condition involving cytokine production or calling for use in the identification process
BR9502471A (en) Guanidine compound Process for preparing a guanidine compound Pharmaceutical composition Use of a guanidine compound Method for the prophylactic or therapeutic treatment of diseases and process for preparing a pharmaceutical composition
BR9708607A (en) Compound pharmaceutical composition use of a compound process for treating or reducing the risk of inflammatory disease in a patient and for the preparation of a compound and chemical intermediate
BR9607346A (en) Compound use of a compound, pharmaceutical composition and process for the treatment of a mammal and for and preparation of compounds
BR9710376A (en) Antiviral compound use of the same pharmaceutical composition and process for prophylactic or therapeutic antiviral treatment of a human or non-human animal
BR9507771A (en) Processes for the preparation of 1-Butyl-2- (2 '- (2H-Tuetazol-5-IL) -Biphenyl-4-Ilmethyl (-1H-Indol-3-Carboxylic acid)
BR9002901A (en) USE OF 3-HYDROXYBENZOTIOFENES, 3-HYDROXYBENZOTIOFENES, PROCESSES FOR THEIR PREPARATION, COMPOUNDS, PROCESSES FOR THEIR PREPARATION, ENDOPARASITIC COMPOSITES AND THE PROCESS FOR THEIR PREPARATION
BR9610733A (en) Compound processes for the preparation of it and for the treatment of a mammal pharmaceutical composition and use of a compound
BR9610316A (en) Compound process for the production and use of the same process for the treatment of airway disease and pharmaceutical composition
BR9800557A (en) Continuous process for the preparation of 4-aminopiperidines
BR9602337A (en) Compound process for its preparation uses the same process for treating arrhythmias and medication
BR9202446A (en) DENTIFICATION COMPOSITION, DENTIFICATION AND PROCESS FOR THE PREPARATION OF A DENTIFICATION
BR9605759A (en) Continuous process for the preparation of 4-mino-2,2,6,6-tetramethylpiperidine
BR9400338A (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethane and pentafluorethane
BR9707173A (en) Process for the preparation of a compound and compound
BR9300034A (en) COMPOUND, PROCESS FOR ITS PRODUCTION AND HEALING COMPOSITION

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]